Heart Association functional class III and IV). In recent years, significant technologic improvements in the field of mechanical circulatory support have led to the development of smaller and more reliable continuous-flow blood pumps resulting in improved morbidity and mortality (2) . In addition to these full-support devices, the concept of partial support has been successfully demonstrated in "less sick" patients (i.e., not sick enough to justify the use of full-support left ventricular assist devices [LVADs] ). One such partial-support system-the Synergy CircuLite Micropump (CircuLite Inc., Saddle Brook, New Jersey)-has been used successfully to treat this patient group, as described previously (3) .
In addition, our group showed that this pump was also capable of supporting inotropic dependent patients and those in cardiogenic shock (4). However, despite initial successes with demonstrated improvements hemodynamics and quality of life, the Synergy had to be withdrawn from the market and is currently undergoing design enhancements to resolve issues that became evident during initial clinical use.
In contrast to partial-support LVADs such as the Synergy, the C-Pulse is an extravascular device that eliminates the need for systemic anticoagulation, Finally, we agree that if a patient has intractable arrhythmias, which impair the delivery of the C-Pulse therapy, they may not be an appropriate candidate for C-Pulse therapy. However, most cases of arrhythmia can be successfully treated to allow synchronization of the C-Pulse system with the native cardiac rhythm. 
B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N

